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Abstract: Curcumin derivatives labelled with fluorine-18 or technetium-99m have recently shown
their potential as diagnostic tools for Alzheimer’s disease. Nevertheless, no study by exploiting the
labelling with gallium-68 has been performed so far, in spite of its suitable properties (positron emitter,
generator produced radionuclide). Herein, an evaluation of the affinity for synthetic β-amyloid fibrils
and for amyloid plaques of three nat/68Ga-labelled curcumin analogues, namely curcumin curcumin
(CUR), bis-dehydroxy-curcumin (bDHC) and diacetyl-curcumin (DAC), was performed. Affinity and
specificity were tested in vitro on amyloid synthetic fibrils by using gallium-68 labelled compounds.
Post-mortem brain cryosections from Tg2576 mice were used for the ex vivo visualization of amyloid
plaques. The affinity of 68Ga(CUR)2+, 68Ga(DAC)2+, and 68Ga(bDHC)2+ for synthetic β-amyloid
fibrils was moderate and their uptake could be observed in vitro. On the other hand, amyloid
plaques could not be visualized on brain sections of Tg2576 mice after injection, probably due to the
low stability of the complexes in vivo and of a hampered passage through the blood–brain barrier.
Like curcumin, all nat/68Ga-curcuminoid complexes maintain a high affinity for β-amyloid plaques.
However, structural modifications are still needed to improve their applicability as radiotracers
in vivo.
Keywords: curcumin; alzheimer disease; Gallium-68; β-amyloid; curcuminoid complexes; fluorescence
1. Introduction
The accumulation of amyloid-β (Aβ) aggregates as soluble oligomers and senile plaques in
the brain are key landmarks for Alzheimer’s disease (AD) and their presence can be exploited
as a selective target for diagnostic and therapeutic drugs [1,2]. Recently, several studies revealed
that (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione also known as curcumin
showed high affinity for Aβ-amyloid plaques in vitro and in vivo and anti-AD properties due to its
ability to bind and subsequently disrupt the aggregation of amyloid peptide and already formed fibrils
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as well [3,4]. Due to this finding, radio-labelled curcumin derivatives could be potential biomarkers for
imaging of Alzheimer’s disease by means of nuclear medicine imaging techniques. The qualitative and
quantitative detection of amyloid deposits could likely play an important role for the early diagnosis
and for the monitoring of the progression of Alzheimer’s disease as Aβ-fibrils’ accumulation occurs
early before clinical symptoms appear. Curcumin is a phyto-compound extracted from the roots of
Curcuma longa L. with strong antioxidant and anti-inflammatory properties that exhibits a pH and
solvent dependent keto-enol tautomerism. Moreover, curcumin is a fluorochrome emitting in the
visible spectrum between 450 and 650 nm. Unfortunately, native curcumin exhibits poor physiological
properties such as low bioavailability, poor water solubility and low stability [5]. Hence, structural
modifications are needed both for stabilizing the molecule as well as for labelling the stabilized
derivatives with the proper radionuclide. A first way for achieving these aims was obtained by simple
addition of a pendant arm with a suitable leaving group to the curcumin structure with the main
purpose of allowing the labelling with fluorine-18 [6,7]. Recent studies provided for more complicated
modifications of the backbones in order to obtain higher stability of the precursor as well as an easier
way for introducing the fluorine-18 atom [8]. In the last years, synthesis, radio-labelling and pre-clinical
applications of this class of compounds were investigated generally achieving positive results in vitro
but failing in their performances in vivo.
A second way was explored by studying the properties of the curcumin/curcuminoids complexes
as these compounds often exhibit higher solubility in aqueous media than free ligands and the
coordinating metal could be quite easily selected in the plethora of the radiometals suitable for nuclear
medicine applications. In fact, by using the curcuminoids as complexing agents, it is possible both
to improve the physiological properties of the derivative and to introduce a radionuclide useful for
imaging purposes. In a recent publication, curcumin was employed as OO bidentate ligand in some
complexes with a technetium-99m tricarbonyl core. This class of radiotracers showed a high affinity
for Aβ-amyloid plaques ex vivo on a section of brain tissue of a neuropathologically diagnosed AD
patient [9].
If compared with fluorine-18 and technectium-99m, gallium-68 exhibits advantageous features
being a generator produced positron emitter radionuclide with physical and chemical characteristics
suitable for diagnostic nuclear medicine and direct labelling of biomolecules (89% β+, maximum
energy = 1.92 MeV; T1/2 = 67.7 min). Speculating on the fact that curcumin complexes appear
to maintain the properties of free curcumin regarding the affinity to amyloid plaques, three new
gallium-68 labelled curcuminoids complexes, namely 68Ga(CUR)2+, 68Ga(DAC)2+, 68Ga(bDHC)2+
whose general structure is reported in Figure 1, were recently synthesized and characterized [10].
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Figure 1. Chemical structure of investigated Ga–curcuminoids complexes. The apical positions of the 
pseudo-octahedral coordination of the metal core are likely occupied in solution by labile ligands such 
as Cl− anions or water molecules. 
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The aim of the following study is to investigate the biological properties in vitro and in vivo of the
three nat/68Ga-curcuminoids complexes exploiting both the intrinsic fluorescence of these derivatives
and the radioactive properties of gallium-68. The results will give insight into the possibility to
employ these compounds as radiotracers for monitoring the presence of Aβ-amyloid plaques in vivo
by positron emission tomography (PET).
2. Results
2.1. Radiosynthesis
Synthesis of 68Ga-labelled curcuminoids was accomplished in 10 min in quantitative yield and
radiochemical purity >95%. Batches of ca. 100 MBq with a specific activity of ca. 2 MBq/nmol
were synthesized for the in vitro studies. When necessary, the batches were diluted in a Dimethyl
sulfoxide(DMSO)/H2O 10/90 solution. A paradigmatic high-performance liquid chromatography
(HPLC) chromatogram of 68Ga(CUR)2+ and free-Ga3+ was shown in Figure 2.
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Figure 2. Comparison between radio-HPLC (high-performance liquid chromatography)
chromatograms obtained from 68Ga(CUR)2+ complex and free-68Ga3+ attesting the completion of
the reaction and the radiochemical purity of the product.
2.2. In Vitro Study
Images of the synthetic β-amyloid fibrils incubated in presence of CUR and of the Ga–curcumin
complexes are gathered in Figure 3.
While the fluorescence associated to free CUR/fibrils complexes is relatively low, the fibrils
incubated wi h the Ga-cur uminoids could be clearly visualized due to the intense fluorescence.
Since an extremely low auto-fluorescence was associated with the untreated fibrils, these findings
qualitatively attest the capability of the Ga–curcuminoid complexes to visualize the synthetic fibrils
depositions. In particular, the fluorescence intensity appears to follow this trend: Ga(CUR)2+ ≥
Ga(DAC)2+ ≈ Ga(bDHC)2+ >> CUR.
To better analyse the affinity of the complexes for the Aβ-fibrils, the curcuminoids were labelled
with gallium-68 and binding experiments were carried out exploiting the radioactive emission of the
compounds. The percentages of the radioactivity bound to the Aβ-fibrils pellets before and after the
displacement with an excess of un-labelled curcuminoids are shown in Figure 4.
Both 68Ga(CUR)2+ and 68Ga(DAC)2+ complexes are strongly retained by the fibrils (>90% bound)
but quite easily displaced by the addition of an excess of correspondent curcuminoid (ca. 45%
bound after displacement). Conversely, 68Ga(bDHC)2+ complex has a lower affinity for the fibrils
(ca. 50% bound) but the compounds remain almost completely associated to the pellets also after the
displacement test.
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2.3. Animal Studies: Ex Vivo Visualization
The affinity for β-amyloid plaques in vivo of the three Ga–curcuminoid complexes was assessed
using post-mortem brain cryosections from male Tg2576 mice. After injection of the compounds,
the brains were explanted and the uptake was visualized exploiting their intrinsic fluorescence.
Micrographs of hippocampal sections of a mice injected with Ga(CUR)2+ are shown in Figure 6.
Although the formation of the amyloid plaques could be attested by the Ga(CUR)2+ direct staining
(panel C) and confirmed by the 6E10 immuno-staining ex vivo (panel A), no fluorescent signal,
derived from the intra-peritoneal injection, of the Ga(CUR)2+ complexes could be visualized (panel B).
Comparable images were obtained for Ga(DAC)2+ and Ga(bDHC)2+ complexes (data not shown).
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Conversely, the Aβ-plaques were clearly visualized by all the Ga–curcuminoid complexes when
mice brain sections were directly stained with the compounds. The specificity of the uptake was
attested by comparison with Congo-Red staining obtaining a high correspondence between the
β-amyloids deposit visualized by the complexes and the reference compound (Figure 7, right panels).
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3. Discussion
Alzheimer’s disease (AD) is the fifth leading cause of death in the elderly population and its
incidence is a true medical emergency. AD is characterized by an extensive brain atrophy and by the
presence of typical brain lesions, namely senile plaques and neurofibrillary tangles. The discovery
that the accumulation of β-amyloid protein [11], resulting in plaque formation, is behind the onset of
Alzheimer’s disease, allowed to identify these deposits as potential molecular targets for diagnostic
and therapeutic purposes.
Diagnosis of AD is often very difficult at the early stages of the disease as it is scarcely
distinguished from normal cognitive aging disorders. Moreover, while Computed Tomography
and Magnetic Resonance Imaging are indispensable tools for the diagnosis of vascular dementia, the
use of these techniques in degenerative dementia does not give a specific contribution at diagnosis
since the differentiation between a brain atrophy and a brain cognitively unscathed is often difficult in
the elderly.
On the other hand, the use of 18FDG-PET (fluorodeoxyglucose-positron emission tomography)
was proposed as imaging techniques for AD detection since it could enable the early detection of
pathophysiologic changes in patients with dementia and allow differential diagnosis [12]. However, as
the 18FDG retention in the brain is an unspecific indicator of metabolism, it can be unbalanced, for
instance, in the presence of ischemia or inflammation and could be undetectable in some people [13].
Nevertheless, due to the great potential of PET imaging, in the last years, the attention was directed
to the identification and development of other highly specific radiotracers, and three 18F-labelled
agents for imaging β-amyloid in the setting of Alzheimer’s disease were recently approved by the
US Food and Drug Administration: florbetaben, flutemetamol and florbetapir [14–16]. However, to
the knowledge of the authors, no gallium-68 labelled radiotracer has been proposed for the imaging
of β-amyloid plaques so far. Herein, the uptake of three nat/68Ga–curcuminoid complexes (namely,
Ga(CUR)2+, Ga(DAC)2+, Ga(bDHC)2+) into amyloid fibrils and plaques has been investigated both
in vitro and in vivo.
Although the curcumin structure is quite different to the Congo Red one, both the molecules share
a hydrophobic bridge separating two functionalised aromatic rings. In particular, the charged sulfonate
groups on the aromatic rings of Congo Red are replaced by polar methoxyl- and hydroxyl-groups
on curcumin.
In sections of tissue, Congo Red showed high affinity for amyloid and a yellow-green birefringence
under crossed polarisers. Thus, Congo Red is the most popular dye used as a probe for diagnosing
amyloidosis also in AD brains [17]. In the coordination with gallium, curcumin and curcuminoids act
as OO bidentate ligands giving 1:2 metal to ligand complexes. Curcumin affinity for amyloid plaques
was already reported by [3] suggesting that the labelling of curcumin or curcuminoids with gallium-68
or other radionuclides can trigger further advancements in the development of new biomarkers for
imaging of Alzheimer’s disease. The radio-labelling was quantitative (>95%) for all the precursors
yielding cationic complexes whose structure is reported in Figure 1. The in vitro experiments of affinity
versus β-amyloid synthetic fibrils were performed by exploiting both the radioactivity of gallium-68
labelled compounds and the intrinsic fluorescence of the ligands. The results reported in Figure 4
show that 68Ga(CUR)2+, 68Ga(DAC)2+ and 68Ga(bDHC)2+ bind the fibrils with high and medium
affinity, respectively. The binding of Ga(CUR)2+, Ga(DAC)2+ appears also quite specific as >50% of
bound activity is displaced by an excess of free curcumin; conversely, the specificity of 68Ga(bDHC)2+
appears lower than the other complexes. These differences could be ascribed mainly to the lower water
solubility of 68Ga(bDHC)2+ in respect to the other compounds that might influence the rinsing step
in the affinity test. For a more quantitative result, a heterologous competitive binding assay against
curcumin was performed for 68Ga(CUR)2+. Curcumin was chosen as an antagonist displaying high
binding affinity (Ki = 3.57 nM for Aβ fibrils [6] and IC50 ranging from 0.68 to 361 nM depending on
the studies [18]), and, hence, it is a proper competitor for this assay. In Figure 5, the resulting sigmoid
fit is shown and an IC50 value of 1.6 × 10−5 M was calculated. This value is scarcely comparable with
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the results obtained for other radio-labelled curcumin derivatives [7,8] as well as other commercial
fluorinated compounds [14–16], as a wide range of different inhibitors were used.
The synthetic fibrils could be clearly visualised by fluorescence microscopy after incubation with
all the complexes, attesting a noticeable uptake of the compounds in the fibrils (Figure 3). Apparently,
the fluorescence of all the complexes is more intense than the free curcumin one and follows this
trend: Ga(CUR)2+ ≥ Ga(DAC)2+ ≈ Ga(bDHC)2+ >> CUR but this evaluation is merely qualitative and
cannot be correlated with the real uptake of the compounds as many parameters might influence the
fluorescent emissions. As previously reported [10], an interesting parameter to be taken into account in
order to evaluate the effect of metal complexation on fluorescence emission is the quantum yield ratio
(RΦ, defined as the ratio between the fluorescence quantum yield of the metal complex and the free
ligand. CUR and DAC behave similarly with a quenching of fluorescence when gallium ion is added to
give the metal complex formation (RΦ ~0.5 in BSA—bovine serum albumin), while bDHC behaves the
opposite with a RΦ ~2 in BSA. On the other side, the fluorescence emission of gallium(III)–curcuminoid
complexes decreases in the order: Ga(bDHC)2+ ≥ Ga(DAC)2+ ≈ Ga(CUR)2+. Thus, these data overtake
the apparent discrepancy between the similar fluorescence emission of all gallium complexes detected
by fluorescence microscopy and the in vitro experiments of affinity versus β-amyloid synthetic fibrils
quantified by radioactivity emission. In fact, the lower affinity of Ga(bDHC)2+ for β-amyloid fibrils
with respect to Ga(CUR)2+ and Ga(DAC)2+, which is reflected in a lower quantity binding to the fibrils
in the affinity experiments, is balanced by its higher fluorescence emission.
Similarly to free curcumin, the mechanism behind the interaction among Ga-compounds and
amyloids fibrils has not been clarified yet. Recent studies show that theβ-strands, whose amyloid fibrils
are formed, are joined by hydrogen bridges in a rearrangement antiparallel to the direction of the fibril.
The strands forms long “tapes” β-sheet, which are held together by interactions, especially electrostatic,
between the side chains of amino acids [19]. It was observed that the positively charged nitrogen on
the thiazole ring of thioflavin can form hydrogen bonds with amyloid fibrils [20]. Similarly, due to
their unique structural features including a flexible backbone and hydrophobic nature, curcuminoid
complexes might insert among the β-strand and might form hydrogen bonds with the several available
H-donor and acceptor atoms. This hypothesis is reinforced by the fact that free curcumin binds more
strongly to the Aβ aggregate in its more polar keto-enol form than in the di-keto form [21]. On the
other hand, it cannot be excluded that, similarly to the inhibitory activity expressed for some enzymes,
the affinity for the amyloids fibrils may be principally due to some curcumin degradation products
rather than the intact molecule itself [22]. For a structure–activity comparison, the molecules of
thioflavin, congo-red, curcumin, trans-6-(4’-hydroxy-3-methoxyphenyl)-2,4-dioxo-5-hexenal (curcumin
metabolite) and Ga–curcuminoid complexes, are reported in Figure 8.
In addition to the studies in vitro, experiments in vivo using mice spontaneously developing
Aβ-plaques (Tg2576) were conducted as well. Tg2576 mice accumulate amyloid plaques starting from
5–6 months of age and progressing until 12–14 months of age [23]. At the age of sacrifice, animals
display an extensive plaque deposition in the cerebral cortex and hippocampus as shown in Figure 6,
panel A. Differently from the results reported for free curcumin [3], after intra-peritoneal injection
of a Ga(CUR)2+ solution, the micrographs of hippocampal sections showed no binding to plaques,
resulting in the absence of fluorescent signals (Figure 6, panel B). These findings cannot be ascribed
to a reduced affinity of Ga(CUR)2+ for the naturally generated amyloid aggregates with respect to
the synthetic fibrils as, in a second set of experiments where the affinity of the three Ga–curcuminoid
complexes was assessed by direct staining on the brain sections, the plaques were clearly visualized
(Figure 6, panel C and Figure 7).
These results could be related to the impossibility of the Ga–curcuminoid complexes to cross
the blood-brain barrier (BBB) and, more in general, to the low stability in physiological media of the
complexes and of the curcumin like structures themselves. In fact, it was shown that free curcumin,
thanks to its lipophilic nature, crosses the BBB and binds to the amyloids fibrils partially limiting
their aggregation in plaques [3] but, conversely, the positive charge of the complexes may hamper the
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passage to the membrane and consequently limit the capability of the Ga–curcuminoid to bind the
β-amyloid aggregates.
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(D) trans-6-(4′-hydroxy-3-methoxyphenyl)-2,4-dioxo-5-hexenal (curcumin metabolite); (E) Ga(CUR)2+
complex. The counter ion is usually chloride but, more general, depends on the media.
Although DAC and bDHC (unpublished results) are m re stable than cu cumin itself in
physiological environments [24], the complex formation slows down the degradation of curcuminoids
in vitro at least in the first 2 h [25], and all the complexes showed high and comparable stability to
transchelation and transmetalation when challenged with diethylenetriaminepentaacetic acid (DTPA),
Fe3+, Cu2+, and Zn2+ solution [10]. We may not exclude the fact that fast metabolization and chemical
degradation of the gallium complexes take place in vivo. Actually, it is known that curcumin is rapidly
reduced to tetrahydrocurcumin and subsequently converted to ferulic acid and dihydroferulic acid
in the hepatic metabolism following ra id systemic eli ination [26], and this may account for the
reduced bi availability of curcumin and its derivatives after injection. It is like y to suppose that the
Ga–curcuminoid c mpl xes follow a similar metabolic path.
To enhance their bio-stability some adjuvants may be inject that are able to block the metabolic
pathways responsible for curcumin metabolization. In regards to this, it is well known that piperine,
an alkaloid found in black pepper, inhibits hepatic and intestinal glucuronidation, obtaining a greater
bioavailability of curcumin [27]. However, with the aim of the development of a PET radiotracer,
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also the stability of the complexes themselves has to be taken into account since the escape of the
radioactive metal core from the ligand cage would unavoidably lead to the failure of the approach.
68Ga(CUR)2+, 68Ga(DAC)2+, 68Ga(bDHC)2+ showed high stability in human serum but data related
to their behaviour in human blood have not yet been reported [10]. Micro-PET imaging could give
valuable insights to better understand both the stability issue and pharmacokinetic behaviour of this
compounds in vivo in order to project a second generation of gallium-68 labelled curcuminoids.
Another reason for the lack of signal derived from the Ga–curcuminoid complexes in the Tg2576
mice brains might hail from the route of administration of the compounds. In fact, in most of the past
studies, free curcumin has been administered to mouse models in the systemic circulation [3,28–30]
or orally by gavage or supplemented chow [3,4,31,32] while, herein, the complexes were injected
intraperitoneally. Although intraperitoneal administration is considered a parenteral route of delivery,
substances administered intraperitoneally might be subjected to hepatic metabolism before reaching the
systemic circulation because of absorption by mesenteric vessels. Moreover, absorption of substances
following intraperitoneal injection is usually slower than following intravenous injection [33].
4. Experimental Section
4.1. Chemicals
Bachem (Bubendorf, Switzerland) provided us amyloid β-protein (1–40), and reagents and
solvents for synthesis and characterization of the curcuminoids complexes were purchased from
Sigma-Aldrich (Milan, Italy).
A 370 MBq itG 68Ge/68Ga generator was supplied by ITM (Garching, Germany) and Rotem
(Leipzig, Germany) provided us metal free hydrochloric acid (0.1 M). When needed, milliQ water
(resistivity 18.2 Mµ·cm) was used for preparing reagents solutions. Unless differently stated, all
commercial chemicals were used without further purification.
Curcumin[1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione](CUR), diacetylcurcumin
(DAC), bis-dehydroxycurcumin [1,7-bis(3-methoxyphenyl)-1,6-heptadiene-3,5-dione] (bDHC), and
their related complexes with natural and gallium-68 were synthesized and characterized as previously
reported [10,34].
Briefly, 5.7 mM GaCl3 MeOH (Methanol) solutions (2.85 µmol) were added to a 5.7 mM
curcuminoids solution (5.0 µmol) in MeOH/DMSO 3:1 (bDHC) or MeOH (CUR, DAC) to prepare
Gallium(III) complexes and stirring the mixture for 3 h at RT. For the synthesis of gallium-68 complexes,
the curcuminoids were dissolved in acetonitrile (ACN) (DAC, bDHC) or EtOH (CUR) in order to
obtain 1 mg/mL solutions and the 68Ge/68Ga generator was eluted with 4 mL of metal free 0.05 M
hydrochloric acid.
Sixty nmol of curcuminoids were then added to 350 µL (about 72 MBq) of the generator eluate and
subsequently were combined with 35 µL of 1.5 M sodium acetate (pH 5). The mixture was heated at
90 ◦C for 10 min and the completion of the labelling was assessed by UHPLC (Ultra High Performance
Liquid Cromatography) or TLC (Thin-layer chromatography).
When used for in vivo experiments, the methanol solutions of Ga(CUR)2+ were evaporated to
dryness and the residue was collected and dissolved in a DMSO/H2O solution 10/90 v/v. The 6E10
anti-Aβ1-16 monoclonal antibody and rhodamine Red-X-secondary antibody were purchased from
Signet Laboratories (Dedham, MA, USA) and Jackson ImmunoResearch (Baltimore, PA, USA),
respectively. Congo-Red staining kit was acquired from Histo-Line Laboratories (Milan, Italy).
4.2. Statistics
Mean values were calculated from the individual measurements and expressed at a precision of
one standard deviation. Unless differently stated, all the experiments were performed in triplicate.
Competitive binding assay analysis and sigmoid fitting were performed with an Origin 6.0 software
(OriginLab Corporation, Northampton, MA, USA).
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4.3. Instrumental Analysis
Tissue observation and analysis were performed with Eclipse E600 Nikon microscope equipped
with an appropriate filter set (fluorescein isothiocyanate (FITC) filter set: excitation 465–495 nm, barrier
filter 515–555 nm, TRITC: excitation 510–560 nm, barrier filter 590 nm). To evaluate β-amyloid plaque
staining, slides were captured using a digital CCD camera Q Imaging Retiga-2000RV (Q Imaging,
Surrey, BC, Canada).
A MultiScreen Separation System Harvest plate (Millipore, Milan, Italy) equipped with a vacuum
pump and glass fibre plates was used for the competitive binding assay. A dose calibrator
(ISOMED2000, MED Nuklear-Medizintechnik, Dresden, Germany) was employed to measure the
activity. The imagesafter Congo-Red staining was observed and captured by using a Nikon Eclipse Ci
optical microscope.
4.4. In Vitro Study
The preparation of Aβ(1–40) amyloid fibrils was performed according to methods previously
published [35]. Briefly, 0.5 mg of β-amyloid protein was dissolved in 1 mL of filtered
phosphate-buffered saline (PBS), pH 7.4, and magnetically stirred at 760 rpm for 3 days at RT.
The mixture was centrifuged at 25,830× g for 15 min to separate the pellet containing Aβ fibrils
from not-aggregated Aβ proteins, in suspension. The supernatant was discarded, the Aβ fibrils pellet
was washed twice with PBS and subsequently was suspended in 1 mL filtered PBS. A Congo Red
binding assay was performed to validate the fibrils’ formation.
To evaluate the affinity of the compounds for the synthetic amyloid fibrils, the fibrils solution was
stirred in order to homogenize the suspension and aliquots of 20 µL (10 µg) were incubated for 3 h at
37 ◦C with (i) 400 µL of a PBS/MeOH solution (as a negative control) (ii) 400 µL of a 10 µM solution of
CUR in MeOH (iii) 400 µL of a 5 µM solution of Ga–curcuminoid complexes (Ga(CUR)2+, Ga(DAC)2+,
Ga(bDHC)2+) in MeOH. The samples were centrifuged at 25,830× g for 15 min, the supernatant was
removed and pellets were washed twice with filtered PBS 1× before being suspended again in 400 µL
of filtered PBS. A 100 µL of each sample was placed in a cytospin slide chamber and spun at 800 rpm
for 5 min. The slides were carefully removed from the cytocentrifuge and allowed to dry prior to the
visualization by fluorescence microscopy.
To evaluate the specificity of the binding between the curcuminoid complexes and the Aβ
synthetic fibrils, displacement tests were performed as following. Aliquots of 70 µL (35 µg) of amyloid
fibrils were incubated at 37 ◦C for 10 min with 500 µL (ca. 20 MBq) of 68Ga–curcuminoids complexes.
The mixtures were centrifuged at 25,830× g for 15 min, the supernatants were discarded and the pellets
were washed twice with filtered PBS.
Pellets were then measured in the dose calibrator. Displacement was performed by adding
500 µL of a 10 µM solution of curcumin to the 68Ga–curcuminoid complexes/amyloid fibrils pellets.
The samples were homogenised by stirring and the procedure of incubation, centrifugation and
washing described above was repeated. Finally, the samples were measured in the dose calibrator for
evaluating the residual activity bound to the pellets.
Binding affinity studies to Aβ-amyloid synthetic fibrils were performed only for 68Ga(CUR)2+
complex by using heterologous competitive binding assay against curcumin. Aliquots of 30 µL (15 µg)
of amyloid fibrils were dispensed in each well of a MultiScreen Separation System Harvest plate.
Subsequently, 20 µL (1.3 MBq) of a 68Ga(CUR)+2 solution were added to each well followed by 100 µL
of curcumin solutions at concentration ranging from 10−3 to 10−7 M in ethanol. The mixtures were
incubated at 37 ◦C for 10 min and the bound radioactivity was collected on 1.0 µm glass fibre filters
which were then rinsed three times with filtered PBS 1×. Finally, the filters were separated from
the plate and measured in the dose calibrator. In order to compute the amount of 68Ga(CUR)2+
un-specifically bound the bottom of the wells, the procedure described was also replicated by adding
the radioactive compounds to the wells in absence of fibrils. Specific uptake was calculated as MBq
per µg of fibrils after subtracting the value obtained for the un-specific binding. A competitive
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binding curve was constructed from the data by using a sigmoid fit and the half maximal inhibitory
concentration (IC50) was determined.
4.5. Animal Studies: Ex Vivo Visualization
Animal experiments were performed in 18 months old Tg2576 mice (Taconic Europe, Ejby,
Denmark). The Tg2576 mice carry a trans-gene coding for the 695-amino acid isoform of the Swedish
mutation of amyloid precursor protein (APP) and spontaneously develop Aβ deposits with increasing
age [36]. Animal care and treatments were in agreement with the EU Directive 2010/63/EU for
animal experiments and in accordance with protocols approved by the Ethical Committee of Animal
Experimentation, University of Bologna. All efforts were made to minimise the number of animals
used and their suffering
In the first set of experiments, Ga–curcuminoid complexes were prepared at 2 mg/mL in water
solutions containing 10% DMSO and administered through a single intra-peritoneal injection of 100 µL
at a final dose of 10 mg/kg. After 4 h, mice were sacrificed by anaesthetic overdose (Isoflurane 5%,
exposure until one minute after breathing stops). The brains were quickly removed and fixed in
paraformaldehyde 4% and picric acid 14% (pH 6.9) for 24 h. Subsequently, after 48 h of washing in
5% sucrose, the brains were frozen and sectioned (14 µm thick) to include the cerebral cortex and
the hippocampus for the auto-fluorescence visualization. For positive control purposes, adjacent
sections were stained using 6E10 anti-Aβ1–16 monoclonal antibody at a 1:1000 dilution and rhodamine
Red-X-secondary antibody at a 1:100 dilution.
In the second set of experiments, mice were sacrificed without any injection of the Ga–curcuminoid
and the brains were removed and treated as described above. The ex vivo affinity of the
three Ga–curcuminoid complexes was assessed by direct staining on the brain sections adjacent
to those used for the visualization of the amyloid plaques after intra-peritoneal injection.
The cryosections were thawed to room temperature for 15 min and then incubated for 45 min
with 40 µM solutions of the compounds in DMSO [9]. The sections were washed with 40% ethanol
for 1 min, following by rinsing with distilled water for 30 s and visualized by fluorescent microscopy.
For positive control purposes, the same sections were stained with Congo Red by using standard
laboratory procedures [37] and the correspondent regions were visualised by optical microscopy.
5. Conclusions
In this paper, the first gallium-68 labelled compounds potentially directed to the diagnosis
of AD were described. Data collected showed that the curcuminoid complexes have a considerable
(68Ga(CUR)2+, 68Ga(DAC)2+) or moderate (68Ga(bDHC)2+) affinity for both amyloid fibrils and plaques
in vitro. Conversely, all the complexes failed in the detection of the amyloid aggregates in vivo.
Hence, further modification is needed for enhancing the lipophilicity and the stability of this class of
compounds before they could be used for early diagnosis of AD, however, the use of a radionuclide
like gallium-68 opens up new possibilities for the use of curcumin-like structures as PET radiotracers.
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